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Purpose: To assess the diagnostic accuracy of iXip, a novel biomarker for prostate cancer detection at initial
biopsy based on an algorithm including patient age, prostate volume, PSA and PSA-IgM levels,.
Materials and methods: This was a prospective multicenter study involving 426 consecutive men undergoing
initial prostate biopsy with at least 12 cores in a real-life clinical setting. Diagnostic accuracy of iXip for prostate
cancer detection was calculated with AUC and compared to that of prostate volume, PSA and PSA-IgM levels.
The correlation of iXip with tumor aggressiveness, deﬁned as any cancer with Gleason score ≥7, was evaluated
by Spearman ρ coeﬃcient analysis.
Results: Prostate cancer was diagnosed in 193/426 patients (45%), of which 65 (35%) had Gleason score ≥7.
iXip values were signiﬁcantly higher in patients with cancer than in those without cancer (median value 55% vs.
39%, p < 0.001). iXip was the most accurate predictor of cancer (AUC=0.711), followed by prostate volume
(AUC=0.660) and PSA level (AUC=0.543). By setting iXip cut-oﬀ at 20%, no patients with iXip values below the
cut-oﬀ were diagnosed with cancer, resulting in a 5.6% (24/426) reduction of unnecessary prostate biopsies. A
signiﬁcant correlation between iXip values and Gleason score was observed (ρ=0.347; p < 0.001).
Conclusions: Our prospective multicenter study suggests that the novel biomarker iXip may be used with a 20%
cut-oﬀ value in order to reduce the proportion of prostate biopsies by approximately 5%, without missing a
single case of cancer. Moreover, higher iXip values are signiﬁcantly correlated with tumor aggressiveness.
1. Introduction
Serum Prostate-Speciﬁc Antigen (PSA) has a low sensitivity and
speciﬁcity for prostate cancer (PCa) detection, especially in the inter-
mediate range of total PSA (tPSA) between 2.5 and 10 ng/mL [1].
Derivative parameters that have been proposed over the past decades
have been disappointing, with the consequence that approximately 3
out of 4 men currently undergoing prostate biopsy (PB) do not have
PCa, and are thus exposed to unnecessary and potentially morbid
procedures [2].
Three recently developed tests, progensa (PCA3) [3], prostate
health index (PHI, [−2]proPSA) [4], and the 4 K score [5] have been
shown to improve the accuracy of tPSA and its derivatives for PCa
detection, and have been proposed as complementary tools to tPSA to
reduce the number of unnecessary PBs. These tests provide a risk
estimation of PB-detectable PCa, but in all cases sensitivity does not
reach 100% when a given cut-oﬀ value is set, implying that none of
them allows the reduction of PBs number without missing real cases of
PCa.
A novel biomarker for PCa detection was recently introduced based
on the observation that, in men with PCa, serum PSA can be detected
as PSA-IgM immune complexes, in which PSA is bound to IgMs [6].
This reﬂects an innate immunity phenomenon, which has been
previously observed for other biomarkers associated with other malig-
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nancies, including squamous cell carcinoma antigen for hepatocellular
carcinoma and carcinoembriogenic antigen for colon carcinoma [7,8].
A prostate biopsy has a slight risk of causing problems such as
infection, bleeding into the urethra or bladder, bleeding from the
rectum and allergic reaction to the anesthetic medicines used during
the biopsy. These are some reasons to research novel non or minimal
invasive methods for biopsy reduction.
To investigate the application of PSA-IgM immune complexes in the
clinical practice, we have developed an algorithm that combines PSA-
IgM levels with patient age, prostate volume and tPSA to obtain a
predictive index, called iXip [9]. Unlike other biomarker algorithms for
PCa detection, where the biological rationale is unclear, iXip was
developed to correlate the levels of the novel biomarker PSA-IgM with
established variables that are biologically associated with PCa. Of note,
the algorithm has been developed in order to optimize the receiver
operating characteristic (ROC) curve at its ends, rather than to obtain
the best possible curve based on the highest area under the ROC curve
(AUC) value. This was done to get > 10% sensitivity at 100% speciﬁcity
and > 10% speciﬁcity at 100% sensitivity. The algorithm has been
tested in an exploratory, proof-of-principle study in 160 men under-
going initial PB, who could be stratiﬁed by their risk of having biopsy-
detectable PCa based on their iXip value. In this study, no patient with
a ≤20% iXip value had PCa at PB, thus suggesting that iXip may be
used to reduce the number of PBs without missing any PCa case.
The present study had two objectives: 1) to prospectively validate
the diagnostic accuracy of iXip (previously elaborated and applied with
no modiﬁcation) for PCa detection in a large, external, multicenter
cohort of men undergoing initial extended PB in a real-life clinical
setting; 2) to evaluate the association of iXip with PCa aggressiveness at
PB.
2. Patients and methods
2.1. Study design and participants
This was a prospective multicenter observational study of diagnos-
tic accuracy approved by the Institutional Review Board for Human
Subjects Research of the University of Padua (N. 0050868) and
designed, conducted and reported according to the Standards for the
Reporting of Diagnostic Accuracy Studies guidelines [10].
Between March 2010 and December 2011, all consecutive patients
referred for PB to one of ﬁve urology departments located in North-
Eastern Italy (Belluno, Brescia, Camposampiero, Padua and
Pordenone) were screened for possible involvement in the present
study. Inclusion criteria were: age > 18 years, abnormal digital rectal
examination, and serum tPSA level > 4 ng/mL or > 2.5 ng/mL in case
of familial history. Exclusion criteria were: previous PB, previous
prostate surgery, previous or concomitant malignancies, active infec-
tions, autoimmune diseases, and medication with steroids, immuno-
suppressive drugs and/or 5α-reductase inhibitors. Of 500 screened
patients, 426 were eventually enrolled in the study after providing
written informed consent (Fig. 1).
2.2. Study protocol
Before any prostatic manipulation, a serum sample was collected.
tPSA and free PSA (fPSA) levels were determined using Hybritech
Access test on UniCelDxI800 (Beckman Coulter, Brea, CA, USA). PSA-
IgM levels were measured in duplicate using Prostate-IC ELISA kit
(Code XG007, Xeptagen SpA, Venice, Italy) with a < 15% variation
coeﬃcient. Prostate-IC was performed on DSX Automated ELISA
System (Dynex Technologies Inc., Chantilly, VA, USA), a computer-
controlled microplate processing system that fully automates ELISA
assays. The iXip index was calculated as previously reported [9].
All patients underwent a systematic TRUS-guided PB with an
extended scheme consisting of at least 12 cores taken from the
peripheral zone (apex, midgland and base) with additional cores taken
when necessary or in case of increased prostate volume. Immediately
before sampling, prostate volume was measured with TRUS using the
ellipsoidal prolate formula. Specimens were collected in single-core
containers, and centrally evaluated by a single experienced genitour-
inary pathologist blinded to all clinical data. PCa was identiﬁed and
graded according to the 2005 ISUP modiﬁed Gleason grading system
[11]. Patients diagnosed with high-grade intraepithelial neoplasm or
atypical small acinar proliferation were considered negative for PCa.
2.3. Study endpoints
The primary endpoint was the diagnostic accuracy of iXip (index
test) compared to tPSA (reference test) for PCa detection at initial
extended PB. The proportion of PBs that could be spared if the index
test had to be used in the decisional PB pathway was also calculated.
Secondary endpoint was the correlation between iXip and PCa aggres-
siveness, which we deﬁned as any Gleason score (GS)≥7 cancer, in line
with previous similar diagnostic studies [12,13].
2.4. Statistical analyses
Given a PCa rate at biopsy of 0.45, 1-β > 95% and α=5%, sample
size was 300 patients. The Kolmogorov-Smirnov test was used to assess
the normality of continuous variables. Student t test, Wilcoxon rank-
sum or χ2 test with Yates continuity were used for comparisons of
normally and non-normally distributed variables as appropriate.
Correlation was assessed by Spearman's rank coeﬃcient analysis.
Diagnostic accuracy for each marker was quantiﬁed with AUC. The
gain in diagnostic accuracy was calculated, and AUCs were compared
using the Hanley and McNeil method [14].
Multivariable logistic regression models to predict PB-detectable
PCa were ﬁt including tPSA and prostate volume as explanatory
variables.
For all comparisons, a two-sided p value < 0.05 was accepted as
signiﬁcant. All analyses were performed using R v.3.0.1 (The R
Foundation for Statistical Computing, Vienna, Austria) and SPSS
Gleason Score < 7
n = 126
Gleason Score ≥ 7
n = 67
Prostate Cancer
n = 193
NO Prostate Cancer
n = 233
Screened Patients
n = 500
Index Test
n = 426
Reference Standard
n = 426
Excluded Patients
Repeat Biopsy n = 74
Fig. 1. Standards for the Reporting of Diagnostic Accuracy Studies ﬂow diagram.
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v.16.0.1 (IBM Corp., Armonk, NY, USA) software.
3. Results
Table 1 summarizes patient characteristics. PCa was detected in
193 of 426 patients (45.3%). Of the 193 patients with PCa at PB, 126
(65%) had a GS < 7 and 67 (35%) had a GS≥7 cancer. tPSA values did
not signiﬁcantly diﬀer between men with or without PCa. Prostate
volume was signiﬁcantly higher in patients without PCa compared to
their counterparts with PCa. Conversely, patients without PCa had
signiﬁcantly lower iXip values than patients with PCa.
iXip was the most accurate predictor of PCa (AUC=0.694) com-
pared to prostate volume (AUC=0.660), tPSA (AUC=0.543) and fPSA
(AUC=0.580) levels (Table 2 and Fig. 2).
As shown in Table 2, the cut-oﬀ for each marker was adjusted in
order to obtain an 11.5% speciﬁcity; then, positive (PPV) and negative
(NPV) predictive values were calculated. In more than 1:10 men
without PB-detectable PCa, iXip was able to properly identify the
unnecessary biopsies (100% NPV). All other markers had a NPV < 90%
and did not correctly distinguish between patients with or without PB-
detectable PCa.
According to the iXip values obtained, patients were arbitrarily
stratiﬁed into four diﬀerent risk groups with no, low, intermediate, or
high likelihood of PB-detectable PCa (Table 3). At a 20% iXip cut-oﬀ
(no-risk group), sensitivity was 100% and speciﬁcity 11.5%, meaning
that all patients with iXip values equal to or lower than 20% had no PB-
detectable PCa. None of the other variables achieved this condition. At
a 30% iXip cut-oﬀ (low-risk group), there was a 2.8% likelihood of
detecting PCa. Avoiding PB in these patients could have spared 92
(21.6%) PBs at the price of missing 12 (6.2%) cases of PCa. However, in
this risk category, only a minority (3/12) of patients had a GS ≥7
cancer (Table 3). For intermediate-risk category, the reduction of
unnecessary PBs would have been higher (57%), but 21% of patients
would have had their PCa missed.
Patients with GS ≥7 cancers showed signiﬁcantly higher iXip values
than those with GS < 7. In patients with iXip values > 50%, the
majority of GS 8 (10/15, 66%) and GS 9 (8/9, 89%) cancers could be
found. Also, iXip was a more accurate predictor of high-grade cancer
(AUC=0.767) than of any-grade cancer (AUC=0.694) (Table 4 and
Fig. 2). Determination of sensitivity and speciﬁcity at diﬀerent iXip cut-
oﬀ values in whole population and stratiﬁed by GS conﬁrmed the
correlation between iXip values and PCa aggressiveness. In fact, at
diﬀerent iXip cut-oﬀ values and ﬁxed speciﬁcities, the sensitivity is
always considerably higher in cancer patients with GS ≥7(Table 5).
No signiﬁcant diﬀerence in iXip performance was observed between
the whole cohort and patients with tPSA levels lower and greater than
10 ng/mL (AUC comparisons, p=0.428 and 0.470, respectively).
Spearman ρ coeﬃcient analysis demonstrated a signiﬁcant correla-
tion between iXip and GS (ρ=0.347, p < 0.001).
4. Discussion
In a large, multicenter, prospective and external cohort of men
submitted to ﬁrst extended PB, we demonstrated that iXip was an
accurate predictor of PCa and was able to stratify the risk of PB-
detectable PCa, with lower values indicating a lower risk of detecting
PCa. In particular, the previously identiﬁed iXip value of 20% was
conﬁrmed to be a relevant cut-oﬀ, below which no single case of PCa
was diagnosed. The main clinical implication of our study is that the
novel biomarker iXip can safely reduce the number of unnecessary PBs.
To the best of our knowledge, this is an unprecedented ﬁnding. In
fact, for none of the available diagnostic biomarkers used for PCa
Table 1
Descriptive characteristics of the study population.
Absence of PCa Presence of PCa Overall p-Value
Patients (%) 233 (54.7%) 193 (45.3%) 426 (100%) NA
Agea (range) [yr] 65.0 ± 6.9 67.4 ± 8.0 66.1 ± 7.5 < 0.001*
Patients with tPSA levels in the range 4÷10 ng/mL 158 (37.1%) 112 (26.3%) 270 (63.4%) < 0.05°
Patients with abnormal DRE (%) 56 (13.1%) 92 (21.6%) 148 (34.7%) < 0.001°
Patients with tPSA levels in the range 4÷10 ng/mL and abnormal DRE (%) 27 (6.3%) 40 (9.4%) 67 (15.7%) < 0.05°
Gleason score at prostate biopsy (%)
< 7 NA 126 (29.6%) NA NA
≥ 7 NA 67 (15.7%) NA NA
Prostate volume (range)b [mL] 47.0 (33.1÷70.0) 35.0 (27.0÷48.0) 40.0 (30.0÷60.0) < 0.001#
tPSA (range)b [ng/mL] 5.8 (4.6÷8.5) 6.0 (4.5÷10.0) 5.9 (4.5÷8.9) 0.130#
fPSA (range)b [ng/mL] 0.81 (0.46÷1.25) 0.55 (0.35÷0.88) 0.67 (0.39÷1.10) < 0.01#
%fPSA (range)b [%] 13.0 (9.6÷18.7) 11.0 (7.25÷15.9) 12.4 (8.3÷17.0) < 0.05#
PSA-IgM (range)b [AU/mL] 78.0 (43.6÷152.9) 76.7 (36.0÷145.1) 77.2 (39.9÷149.0) 0.613#
iXip (range)b [%] 39.2 (27.2÷54.7) 55.2 (41.3÷66.1) 45.5 (31.8÷62.0) < 0.001#
iXip (range)b [%]
Gleason score (%) < 7 39.2 (27.2÷54.7) 51.3 (39.1÷65.2) 43.0 (30.2÷59.4) < 0.001#
iXip (range)b [%]
Gleason score (%) ≥7 39.2 (27.2÷54.7) 59.6 (48.1÷67.6) 43.9 (29.2÷60.2) < 0.001#
DRE=digital rectal examination; fPSA=free PSA; NA=not applicable; PCa=prostate cancer; PSA=prostate-specific antigen; tPSA=total PSA; %fPSA=percentage of free PSA to total PSA.
a data are expressed as mean and standard deviation.
b data are expressed as median and interquartile range.
# Wilcoxon rank sum (Mann–Whitney) test.
* Student t test.
° x2 test with Yates continuity correction.
Table 2
Diagnostic performance of tumor markers, diagnostic parameters and multivariable
models (prevalence 45%).
Variable AUC Sensitivity NPV PPV
(Speciﬁcity 11.5%)
tPSA 0.543 88.1% 52.7% 45.1%
%fPSA 0.603 94.3% 70.0% 46.7%
Prostate volume 0.682 97.4% 83.6% 47.5%
PSA-IgM 0.514 86.0% 48.7% 44.5%
Base modela 0.723 97.4% 83.8% 47.6%
Base modela+Age 0.755 96.4% 78.7% 47.3%
iXip 0.711 100.0% 100.0% 48.2%
AUC=area under ROC curve; NPV=negative predictive value; PPV=positive predictive
value; tPSA=total PSA; %fPSA=percentage of free PSA to total PSA.
a Base Model=tPSA+prostate volume.
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detection, including the newest ones, PCA3 and PHI, a cut-oﬀ value has
been identiﬁed that gives 100% sensitivity or speciﬁcity. Both PCA3
and PHI have been shown to improve discrimination between men
with and without PCa, mainly in the tPSA range 2.5–10 ng/mL, and
between cases of clinically signiﬁcant and insigniﬁcant disease
[12,13,15]. As for PCA3, the likelihood of positive PB is 17% for a
score < 35, 43% for a score > 35, and 69% for a score > 100 [15]. Even
in the lowest score category, there is a non-negligible likelihood of
ﬁnding PCa. Moreover, the EGAPP Working Group judged the perfor-
mance of PCA3 testing inadequate to inform doctors as when to repeat
the biopsy for prostate cancer in previously negative patients, or when
to conduct initial biopsies in at-risk men [16].
As for PCa risk determined with PHI, in the range 0–20.9 there is a
low risk (8,4% of probability), and in the range 21–39.9 there is a
moderate risk (21% of probability), while with a PHI > 40 there is a
high risk (44% of probability) [13]. Thus, even in the lowest PHI range,
there still is a consistent probability to miss PCa-positive cases; under
the best conditions, for 100 spared biopsies (15.5%), 26 PCa-positive
cases (9.8%) are lost, giving a 3.8 spared/missed ratio [13]. In our
study, by using iXip with a 30% cut-oﬀ, 92 biopsies could be spared
(21.6%), with only 12 cases (6.2%) lost, giving a 7.7 spared/missed
ratio. Although higher PHI index is associated with greater risk of
having prostate cancer, this biomarker is not able to spare unnecessary
negative biopsies without loss of PCa-positive cases.
The proportion of patients with iXip value below the 20% cut-oﬀ,
who may be safely spared PB, represents 5.6% (24/426) of the entire
cohort. It may be argued that this rate is low. However, due to the
accumulating bulk of literature reporting on increasing rate of infec-
tious and potentially lethal complications following PB [17–19], we
believe this rate is clinically signiﬁcant. In addition, reducing even a
small proportion of PBs translates into a signiﬁcant cost reduction,
considering the millions of procedures that are routinely performed
worldwide every year.
This study also conﬁrms a previously found correlation between
iXip values and PCa aggressiveness, deﬁned at PB as GS ≥7 cancers.
Higher iXip values were signiﬁcantly associated with higher-grade
cancers. Future research should focus on the identiﬁcation of a cut-oﬀ
Fig. 2. A) Receiver operating characteristic curves depicting the accuracy of individual predictors of any prostate cancer. B) Receiver operating characteristic curves depicting the
accuracy of individual predictors of Gleason score ≥7 prostate cancer.
Table 3
Stratification of iXip values into risk categories with corresponding proportion of
avoidable prostate biopsies.
Risk No Low Intermediate High
iXip cutoﬀ 20% 30% 50% 80%
Sensitivity 100% 93.8 59.6% 2.1%
Speciﬁcity 10.3% 34.3% 70.8% 100%
Patients without PCa 24/233 80/233 165/233 233/233
Reduction of PCa-
negative biopsy
10.3% 34.3% 70.8% 100.0%
Spared/missed
ratio
– (24/0) 7.7 (92/
12)
3.11 (243/78) 2.23 (422/
189)
Patients with PCa 0/193 12/193 78/193 189/193
Gleason score < 7 (%) 0 (0.0%) 9 (75.0%) 60 (76.9%) 123 (65.0%)
Gleason score=7 (%) 0 (0.0%) 2 (16.7%) 12 (15.4%) 42 (22.2%)
Gleason score=3+4
(%)
0 (0.0%) 2 (16.7%) 5 (6.4%) 24 (12.7%)
Gleason score=4+3
(%)
0 (0.0%) 0 (0.0%) 7 (9.0%) 18 (9.5%)
Gleason score=8 (%) 0 (0.0%) 1 (8.3%) 5 (6.4%) 15 (7.9%)
Gleason score=9 (%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 9 (4.9%)
Reduction of PCa-
positive biopsy
0.0% 6.2% 40.4% 97.9%
PCa=prostate cancer.
Table 4
iXip values in patients without (controls) and with (cases) prostate cancer at biopsy, the
latter stratified by Gleason score < 7 and ≥7.
Subjects n iXip iXip median W p-
valuea
AUC R p-
valuebmean±SD (min÷max)
Controls 233 40.5 ± 17.5% 39.2% – – –
(0.0÷78.0%)
Cases 193 53.7 ± 15.6% 55.2% <
0.001
0.711 –
(20.8÷90.0%)
Cases 126 51.9 ± 16.5% 51.3% <
0.001
0.682 0.036
Gleason
score
< 7
(20.8÷90.0%)
Cases 67 56.9 ± 13.4% 59.6% <
0.001
0.767
Gleason
score
≥7
(21.1÷81.9%)
AUC=Area under ROC curve between different case subpopulation and control subjects;
SD=standard deviation.
a W p-value=Wilcoxon rank sum (Mann–Whitney) test between diﬀerent case
subpopulation and control subjects.
b R p-value=ROC-AUCs comparison between control subjects and population with
Gleason score < 7 and ≥7.
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value for iXip above which only clinically signiﬁcant disease can be
detected. In our study, increasing the iXip cut-oﬀ to 30% resulted in an
increased number of avoidable biopsies (21.6%), but with 6.2% of PCa
cases being missed. Most of these cases were GS < 7 cancers. We
acknowledge that the deﬁnition of tumor aggressiveness by GS ≥7 is
prone to criticism, however it was used by two recent similar diagnostic
studies [12,13]. iXip, as well as other novel markers, should be
correlated with deﬁnitive pathology after radical prostatectomy, and,
ideally, with oncological outcome after treatment.
Admittedly, the absolute number of patients in the two iXip
categories ≤20% (n=24) and 20%-30% (n=92) was low, therefore we
cannot draw deﬁnitive conclusions. Additional studies with larger
cohorts are required to better characterize patients with iXip values
in these ranges.
A major concern related to PCa screening and early detection is
overdiagnosis and overtreatment of indolent disease. Strategies to
reduce overdiagnosis are necessary, as are strategies to diﬀerentiate
indolent from aggressive cancers. One solution could be performing
PBs only in men with a clinically signiﬁcant and potentially lethal
cancer. Our ﬁndings suggest that the use of iXip could not only safely
avoid unnecessary PBs, but could also maximize the detection of
aggressive cancers.
Our study has several strengths. First, this is one of the few
diagnostic studies testing novel biomarkers which prospectively en-
rolled a large cohort of contemporary PB candidates (n=426) from
multiple clinical centers, using the same operative procedures with
regard to serum sample collection and storage, centralized PSA-IgM
determination, standardized PB protocol and centralized specimen
analysis by a single experienced and blinded genitourinary pathologist.
Second, the large sample size allowed studying the correlation between
iXip and PCa aggressiveness. Third, although the base models have
been calculated on the same cohort, they do not meet the requirements
obtained with iXip to correctly identify men without PB-detectable
PCa. Unlike the base models that are cohort-dependent, iXip was
calculated on a previous independent dataset, and applied and
validated on the current cohort with no modiﬁcation.
We acknowledge the following limitations to our analysis. First,
iXip requires prostate volume to be measured with an invasive exam
(i.e. TRUS), which might limit patient acceptance to testing. Second, it
might well be that adding further variables in our algorithm would
result in a further optimization of the diagnostic performance, which
would translate in a further reduction in the number of unnecessary
PBs. Third, this marker was used in a for-cause cohort of men already
selected for prostate biopsy and may perform diﬀerently in a screening
setting where prevalence of prostate cancer is lower. Fourth, the
diagnostic performance of iXip has to be compared with that of other
novel biomarkers, such as PCA3 and PHI, in formal head-to-head
comparative studies.
5. Conclusions
Our prospective, multicenter study suggests that the novel biomar-
ker iXip may be used with a 20% cut-oﬀ value in order to reduce the
proportion of PBs by approximately 5% without missing a single case of
PCa. Moreover, higher iXip values are signiﬁcantly associated with PCa
aggressiveness, deﬁned as any GS ≥7 cancer at PB.
The implementation of iXip in the diagnostic pathway of early PCa
detection might result in a reduction of the proportion of unnecessary
PBs and in the identiﬁcation of patients with clinically signiﬁcant PCa,
allowing an overall decrease in overdiagnosis and overtreatment.
Additional, large-scale studies are warranted to corroborate our ﬁnd-
ings.
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